Viromed's Cold Plasma Breakthrough in Lung Treatment

Viromed Medical AG, a pioneer in cold plasma technology, has announced the successful completion of multi-year research into the application of cold atmospheric plasma (CAP) in the lung. The study, which focused on ventilator-associated pneumonia (VAP)—a critical challenge in intensive care—confirms the potential of cold plasma as a non-pharmacological treatment. Results show a clearly defined therapeutic safety window and complete reduction of pathogenic germs in lung epithelial models. Key collaborations with Saarland University and Hannover Medical School provided ex vivo validation on vital lungs using an isolated, ventilation- and perfusion-capable model that mimics human lung physiology.

Uwe Perbandt, Member of the Management Board, hailed the milestone as opening a new chapter in intensive care and infectious medicine. The technology has already been applied in a university hospital setting for a severe pulmonary case involving a lung transplant patient with massive complications. The treating physicians reported an exceptional positive clinical course, and further patients at high risk of fatal outcomes are undergoing treatment. Viromed plans to submit the study data for publication in a renowned scientific journal.

Looking ahead, Viromed sees cold plasma technology revolutionizing pneumology by offering a physical mode of action that overcomes antibiotic resistance. Future applications in intensive care include intracardiac use for bacterial endocarditis and thoracic use for pleural empyema. The company, listed since 2022, focuses on distributing innovative cold plasma products via its subsidiary Viromed Medical GmbH, targeting a broad customer base in the DACH region and beyond. For more details, visit the original release on NEWMEDIAWIRE.